Carmy Forney

Carmy Forney

Auto-generated profile, based on publicly available information

Carmy Forney

Cincinnati Children’s Hospital Medical Center (CCHMC), Division of Allergy and Immunology, Cincinnati, OH, United States

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2025 in bioRxiv
Verified
Preprint
Open access
PDPhillip J. Dexheimer
Phillip J. Dexheimer
MHMatthew R. Hass
Matthew R. Hass
LELee E. Edsall
Lee E. Edsall
ADArame A. Diouf
Arame A. Diouf
SJSydney H. Jones
Sydney H. Jones
MWMatthew T. Weirauch
Matthew T. Weirauch
Summary: We systematically investigate interactions between Epstein-Barr virus (EBV) transcriptional regulators (vTRs) and the human genome. Starting with 16 known and candidate vTRs, we identify nine whose introduction into human cells results in substantial alterations to host gene expression. Genome-scale determination of vTR genomic binding events and alterations to chromatin accessibility reveals a detailed map of EBV’s functional interactions with the human genome, including >100,000 vTR binding events impacting almost a quarter of all human genes. BMRF1 emerges as a potent regulator, impacting >7,000 genes and altering >37,000 chromatin regions. Our results provide new evidence that EBV RTA interacts with and stabilizes the binding of human RBPJ. Network analysis reveals that many human genes are targeted by multiple EBV vTRs, highlighting the vast coordinated impact of EBV on human gene expression. This study provides a valuable, extensive resource for examining EBV-induced alterations to human gene regulation, with data available on multiple platforms.

5 December 2025 in bioRxiv
Verified
Preprint
Open access
EPEdwin G. Peña-Martínez
Edwin G. Peña-Martínez
SSShreya Sharma
Shreya Sharma
JMJoshua G. Medina-Feliciano
Joshua G. Medina-Feliciano
ERElise Root
Elise Root
LPLois G. Parks
Lois G. Parks
JRJosé A. Rodríguez-Martínez
José A. Rodríguez-Martínez
(Summary): Genome-wide association studies (GWAS) have mapped thousands of congenital heart disease (CHD)-associated variants within non-coding regions of the genome. Non-coding variants can alter regulatory mechanisms, such as transcription factor (TF) binding control of gene expression, potentially contributing human diseases. However, with the increasing number of disease-associated variants, comprehensive functional validation remains a significant challenge. In this work, we developed a novel method called SNP Bind-n-Seq to evaluate >3,000 CHD-risk variants for allelic binding for the cardiac TFs NKX2-5, GATA4, and TBX5 in a high-throughput manner. These binding affinity data sets were coupled with a massively parallel reporter assay (MPRA) to screen CHD-risk variant genotype-dependent regulatory activity. We identified 170 variants that exhibit allelic TF binding and 187 that modulate gene expression. Combining both approaches revealed three high-confidence variants with genotype-dependent TF binding, genotype-dependent transcriptional activity, and eQTL behavior in cardiac cells. Collectively, this study provides the first combined high-throughput biochemical and functional genomic evaluation of thousands of CHD-risk variants. Highlights: Allelic binding affinity measurements of ∼9,600 variants for NKX2-5, GATA4, and TBX5 EvaluaFon of >3,000 CHD-risk variants for genotype-dependent regulatory acFvity InteracFon networks idenFfy funcFonal variants and genes involving cardiac eQTLs Graphical

23 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MGMarissa Granitto
Marissa Granitto
EKEllie Kim
Ellie Kim
CFCarmy R. Forney
Carmy R. Forney
CYCailing Yin
Cailing Yin
ADArame A. Diouf
Arame A. Diouf
MWMatthew T. Weirauch
Matthew T. Weirauch
Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system affecting 2.8 million people worldwide. Both genetic and environmental factors contribute to MS risk, with Epstein-Barr virus (EBV) infection being an important environmental factor. To better clarify the role of EBV in MS, we examined its impact on gene expression, chromatin accessibility, and transcription factor binding in primary B cells and EBV-transformed B cells derived from patients with MS and healthy controls. RNA-seq and ATAC-seq analyses revealed extensive MS-dependent gene expression and chromatin accessibility differences in EBV-transformed, but not in primary B cells. These changes are largely accounted for by the expression levels of EBNA2, an EBV-encoded transcriptional regulator previously implicated in MS. ChIP-seq analysis revealed that EBNA2 binding with its interacting human partners RBPJ, EBF1, and PU.1 is highly enriched at MS genetic risk loci, with extensive EBNA2 allelic binding and increased enrichment at MS genetic risk loci in MS-derived cells. Our findings demonstrate that enhanced EBNA2 activity in MS alters human gene expression, chromatin accessibility, and transcription factor binding in an MS-dependent manner. Collectively, this study provides new insights into the molecular mechanisms through which EBV, particularly EBNA2, interacts with host genetic risk to contribute to MS pathogenesis.

7 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CSCasey O. Swoboda
Casey O. Swoboda
CFCarmy Forney
Carmy Forney
CCCristofer Calvo
Cristofer Calvo
LLLucinda P. Lawson
Lucinda P. Lawson
HCHilal Cevik
Hilal Cevik
SOShannon K. O’COnnor
Shannon K. O’COnnor
Juvenile dermatomyositis (JDM) is a chronic multisystem vasculopathy and inflammatory myopathy characterized by proximal muscle weakness, distinct rash, and risk of complications such as calcinosis cutis, skin ulceration, and mortality. Molecular insight from diagnostic muscle biopsy histology is limited, and the mechanistic pathoetiology of JDM remains poorly defined. We used single nuclei transcriptomics to assess muscle samples from patients with newly diagnosed treatment-naïve JDM. As a control, we assessed muscle samples from patients with congenital (nemaline) myopathy (CM), a non-inflammatory disorder. A total of 25,794 high quality nuclei were analyzed and clustered into various muscle-resident or infiltrating cellular populations. JDM tissue was characterized by an enriched interferon (IFN) response signature across endothelial, stromal, and immune cell compartments. Endothelial and perivascular populations showed increased inflammatory and angiogenic programs. Intercellular communication inference analysis identified dysregulated vascular endothelial growth factor (VEGF)-related signaling involving endothelial, stromal, and myonuclear populations as a possible mechanism for myonuclear-driven modulation of the muscle microvasculature. Spatial RNA in situ hybridization supported increased expression of selected IFN responsive and angiogenesis signaling genes in JDM tissue. Collectively, these data provide a cell type-resolved view of treatment-naïve JDM muscle and highlight vascular and IFN pathways for follow-up in larger cohorts.

27 January 2026 in medRxiv
Verified
Preprint
Open access
PDF file
DLDavid A. Lewis
David A. Lewis
MSMolly S. Shook
Molly S. Shook
LLLucinda P. Lawson
Lucinda P. Lawson
SPSreeja Parameswaran
Sreeja Parameswaran
XCXiaoting Chen
Xiaoting Chen
LKLeah C. Kottyan
Leah C. Kottyan
Transcription factors play key roles in cellular biology. Their genomic binding events are enriched at disease- and trait-associated genetic risk loci in particular cellular contexts. To examine this phenomenon in depth, we constructed a PU.1 (SPI1) binding atlas by uniformly processing 260 PU.1 ChIP-seq datasets spanning many immune cell types. Comparison of ChIP-seq peaks across eight major immune cell types identifies shared and cell type-specific PU.1 binding events. DNA sequence analyses reveals context-specific binding shaped by both canonical PU.1 motifs and motifs from partner transcription factor families. Integration of this atlas with genome-wide association studies of blood cell traits and immune-mediated diseases reveals strong enrichment for PU.1 binding events at genetic risk loci and extensive genotype-dependent PU.1 genomic occupancy. We identify cellular contexts in which PU.1 enrichment is most pronounced, including at autoimmune disease loci within EBV-positive B cells. Together, these results define cellular, infectious, and genetic contexts of PU.1 binding that help connect noncoding variation to human phenotypes.